You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
Dow
McKesson
Harvard Business School
McKinsey
Mallinckrodt

Last Updated: August 14, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Chidamide

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Chidamide?

Chidamide is an investigational drug.

There have been 67 clinical trials for Chidamide. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2019.

The most common disease conditions in clinical trials are Lymphoma, Lymphoma, T-Cell, and Lymphoma, T-Cell, Peripheral. The leading clinical trial sponsors are Chipscreen Biosciences, Ltd., Sun Yat-sen University, and Ruijin Hospital.

There are three US patents protecting this investigational drug and twenty-eight international patents.

Recent Clinical Trials for Chidamide
TitleSponsorPhase
Neoadjuvant Tucidinostat and Exemestane in Early Breast CancerFirst Affiliated Hospital, Sun Yat-Sen UniversityPhase 2
Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell LymphomaHunan Cancer HospitalPhase 2
Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma Unfit for Conventional ChemotherapyRuijin HospitalPhase 2

See all Chidamide clinical trials

Clinical Trial Summary for Chidamide

Top disease conditions for Chidamide
Top clinical trial sponsors for Chidamide

See all Chidamide clinical trials

US Patents for Chidamide

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Chidamide   Start Trial Histone deacetylase inhibitors Orchid Chemicals & Pharmaceuticals Limited (Chennai, IN)   Start Trial
Chidamide   Start Trial Crystal form of chidamide, preparation method and use thereof SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. (Shenzhen, Guangdong, CN)   Start Trial
Chidamide   Start Trial Agents for killing HIV-1-infected cells and application thereof KAGOSHIMA UNIVERSITY (Kogoshima-Shi, Kagoshima, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Chidamide

Drugname Country Document Number Estimated Expiration Related US Patent
Chidamide Australia 2008309269 1989-12-31   Start Trial
Chidamide Canada 2702536 1989-12-31   Start Trial
Chidamide European Patent Office 2205563 1989-12-31   Start Trial
Chidamide Japan 2011501746 1989-12-31   Start Trial
Chidamide Japan 2014144947 1989-12-31   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
McKesson
Harvard Business School
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.